Previous 10 | Next 10 |
Recursion Pharmaceuticals (NASDAQ:RXRX): Q3 GAAP EPS of -$0.28 in-line. Revenue of $2.53M (+148.0% Y/Y) misses by $0.17M. Press Release For further details see: Recursion Pharmaceuticals EPS in-line, misses on revenue
Recursion Provides Business Updates and Reports Third Quarter 2021 Financials - Received Fast Track Designation for REC-2282, a potential treatment for NF2 meningiomas, and expect to enroll the first patient in a Phase 2/3 trial in early 2022 - Advanced REC-994, a potential ...
The after-effects of pandemic-era policies will be with us for some time - with many supply chains and labor markets still experiencing significant disruption. Everyone likes to complain about drug prices, but here is the unpleasant truth: discovering new drugs is expensive and risky....
Gainers: Jasper Therapeutics JSPR +114%, Clarus Therapeutics (NASDAQ:CRXT) +45%, Alimera Sciences ALIM +19%, Revance Therapeutics RVNC +13%, Recursion Pharmaceuticals (NASDAQ:RXRX) +12%. Losers: NeuroOne Medical Technologies NMTC -25%, Ne...
Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas PR Newswire SALT LAKE CITY , Oct. 7, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by ...
Gainers: ADVM +13.3%. SCPS +9.7%. BIDU +4.1%. AGTC +3.9%. APM +3.5%. Losers: HX -7.3%. NUVL -4.6%. RXRX -2.2%. FA -2.1%. FLYW -1.9%. For further details see: ADVM, SCPS, HX and NUVL among after hours movers
Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis PR Newswire SALT LAKE CITY , Sept. 29, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biolo...
Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets. Public investors can access this disruptive technology at a venture-like valuation. A clean balance sheet funds the business until H2 2023, with ...
Recursion Reports Second Quarter 2021 Financials and Provides Business Updates - Expanded the total number of research and development programs from 37 to 48 - Announced first internally-developed NCE is advancing to IND-enabling studies - Planning to expand operations t...
Mir Basar Suhaib/iStock via Getty Images Recently IPO’ed biotech firms Prometheus Biosciences ([[RXDX]] -21.5%) and Recursion Pharmaceuticals ([[RXRX]] -19.2%) are on course to record their biggest one-day losses since their public debut in March and April, respectively. As demons...
News, Short Squeeze, Breakout and More Instantly...
Recursion Pharmaceuticals Inc. Company Name:
RXRX Stock Symbol:
NASDAQ Market:
Recursion Pharmaceuticals Inc. Website:
2024-07-27 05:41:00 ET Investors looking for stocks that can make dramatic gains often turn toward the biotechnology sector. It isn't unusual for stocks in this industry to shoot higher in response to positive clinical-trial results for experimental new drugs. Recursion Pharmaceutical...
2024-07-13 09:29:00 ET Recursion Pharmaceuticals (NASDAQ: RXRX) is arguably one of the most unique drugmakers on the planet. Though it's classified as a biotech company, its claim to fame is an artificial intelligence (AI)-based approach to speeding up drug discovery and development...
2024-07-11 10:10:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at transformative innovation in biopharma, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmac...